Developer docs
API playgroundTry for free, no card

Search company profiles

Glytec

Full company profile

uuid000092i

Namestring
Glytec
Legal namestring
Glytec, LLC
Websiteurl
glytec.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Glytec is a Greenville/Atlanta-based healthcare technology company that develops and commercializes GlytecOne, a cloud-based, FDA-cleared platform for inpatient glycemic management. Its core engine, Glucommander, is a Class II Software as a Medical Device that has provided algorithm-based insulin dosing recommendations (IV and subcutaneous) since 2006 with zero recalls, and the platform extends into clinical workflow standardization, performance analytics, and population health intelligence across the care continuum. The company serves 400+ U.S. hospitals and health systems through a direct enterprise sales motion, with the 2026 CMS Hospital Harm eCQM mandate (NQF #3503e and #3533e) acting as a primary demand catalyst. Glytec is a wholly-owned subsidiary of Aseko, Inc., and sells primarily via annual subscription SaaS contracts whose pricing varies by hospital size and footprint, reporting customer outcomes of 6-8x ROI, up to 99.8% reduction in severe hypoglycemia events, and 50+ billion data points processed.

The company is led by President & CEO Patrick F. Cua (appointed 2024) and has raised a visible ~$78M across multiple venture and growth rounds, including a $36M growth investment in July 2025 led by Savitr Capital and Hayfin Capital Management. In March 2026 it announced relocation of global headquarters from Boston to Cobb County, Georgia, with 500 new jobs planned over several years. Strategic partners include Premier (Patient Safety Solutions Agreement), Leapfrog (Partner Advisory Committee), Roche (point-of-care device integration), University Hospitals, and Major Health Partners; the company also holds ISO 13485 and HITRUST CSF certifications and has secured 100+ patents and 100+ clinical publications.

Short descriptiontext

Glytec is a U.S.-based healthcare technology company that sells GlytecOne, an FDA-cleared, cloud-based glycemic management platform anchored by the Glucommander insulin dosing algorithm, to 400+ hospitals, health systems, and increasingly to health plans and value-based care organizations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
insulin management software, glycemic management platform, FDA-cleared medical software, clinical decision support, diabetes therapy management
Industry2 codes
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Clinical Decision Support Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Platform Subscription
TypeSubscription Recurring
Description

Glytec operates as a SaaS healthcare technology company offering subscription-based access to its GlytecOne platform. The platform includes FDA-cleared Glucommander insulin dosing software and Command Center analytics. Revenue is generated through annual licensing agreements with hospitals and health systems, with pricing likely based on hospital size or patient volume.

glytec.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise SaaS subscription for hospital glycemic management
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing not publicly disclosed. Quote-based pricing varies by hospital size, number of facilities, and implementation scope. Company promotes 6-8x ROI for customers.

glytec.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1GlytecOne
Description

The first unified glycemic management platform that integrates clinical decision support, workflow automation, performance analytics, and enterprise population health intelligence.

glytec.com
+5 more records
Core offering1 text field

Glytec develops and sells the GlytecOne unified glycemic management SaaS platform for hospitals and health systems. Its core product is Glucommander, an FDA-cleared Class II Software as a Medical Device that provides algorithm-based IV and SubQ insulin dosing recommendations for hospitalized patients. The platform integrates bi-directionally with Epic, Oracle Health (Cerner), and Meditech EHRs and includes Command Center analytics, performance benchmarking, and CMS eCQM reporting.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • Up to 99.8% reduction in severe hypoglycemia events
+9 more records
Product overview1 text field

Glytec offers a unified platform architecture centered on GlytecOne, the first unified glycemic management platform that integrates four pillars: Care Enablement, Decision Support, Performance Insights, and Population Health. The platform's core product is Glucommander, an FDA-cleared Class II Software as a Medical Device providing algorithm-based IV (Glucommander IV) and subcutaneous (Glucommander SubQ) insulin dosing recommendations since 2006. Command Center serves as the clinical data visualization and analytics layer powering both Decision Support and Performance Insights, enabling current patient visibility, structured clinical review, and regulatory-ready eCQM reporting. The Population Health pillar extends enterprise glycemic intelligence to health system leaders and health plan partners. Glytec also offers the CMS Reporting CareKit as a preparation resource for the 2026 CMS mandate. Glytec serves 400+ hospitals and health systems with over 100 patents and 100+ clinical publications validating its outcomes.

Product and service5 records
1GlytecOne
CategoryPlatform
Description

The first unified glycemic management platform that integrates clinical decision support, workflow automation, performance analytics, and enterprise population health intelligence. Built on four pillars: Care Enablement, Decision Support, Performance Insights, and Population Health. Connects care team members and hospital leaders with the data and tools to deliver safer, more consistent glucose management across the entire health system.

2Glucommander
CategoryClinical Decision Support Software (FDA-cleared SaMD)
Description

FDA-cleared Class II Software as a Medical Device (SaMD) providing algorithm-based insulin dosing recommendations for hospitalized patients ages 2 and older. Available in two configurations: Glucommander IV for intravenous insulin dosing in acute and critical care settings, and Glucommander SubQ for subcutaneous basal-bolus insulin dosing in non-ICU and transitional care. Clinicians review and confirm all recommendations before administration. Has zero FDA recall record since 2006.

3Command Center
CategoryAnalytics Module
Description

Clinical data visualization and analytics platform that provides healthcare professionals and administrators with organized displays of current and historical glycemic management information to support quality improvement, care coordination, and clinical review activities. Receives laboratory values, medication administration data, and clinical information from hospital EHR systems and presents this through dashboards, reports, and trend visualizations. Powers the Decision Support and Performance Insights pillars of GlytecOne.

4Glytec CMS Reporting CareKit
CategoryCompliance Resource
Description

A comprehensive resource bundle designed to help hospitals prepare for the 2026 CMS Mandate requiring reporting of severe hypoglycemia (NQF #3503e) and severe hyperglycemia (NQF #3533e) as hospital harm eCQMs. Includes a CMS ruling summary, expert implementation timeline, and a CMS compliance checklist.

5eGlycemic Management System (eGMS)
CategoryPlatform (legacy / superseded by GlytecOne)
Description

Modularized solution for glycemic management across the care continuum, including Glucommander. Supports both IV and SubQ insulin dosing guidance. Superseded by GlytecOne in 2024 as the unified platform architecture.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Glytec and Advocate Health Beverly Knight Olson Children's Hospital won the top innovation award at the Society of Critical Care Medicine's Innovation Incubator for clinical evidence supporting software-guided insulin dosing in pediatric diabetic ketoacidosis patients. The study covered 1,372 children treated with Glucommander showing zero mortality. Glytec plans to continue collaboration through additional pediatric research and publications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Glytec and University Hospitals forged strategic partnership in 2024 to drive continued improvement in patient care and diabetes management. The partnership focuses on clinical collaboration and evidence development for glycemic management.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Glytec and Major Health Partners forged strategic partnership in 2024 to drive continued improvement in patient care and diabetes management through Glytec's eGMS technology.

Strategic tierStrategicTypeTechnology or Integration
Description

Glytec and Roche struck collaboration in 2022 on insulin management diagnostics on handheld point-of-care devices. The partnership enhances interoperability between Roche's diagnostic devices and Glytec's insulin management software.

Strategic tierStrategicTypeImplementation/ SI/ Consulting Partner
Description

Glytec and CPS Solutions, LLC integrated in 2022 to provide evidence-based glycemic management. CPS is a leading provider of enterprise pharmacy solutions to hospitals and health systems.

Strategic tierStrategicTypeGTM or Marketing Partner
Description

Glytec joined Leapfrog's Partner Advisory Committee in 2024 to enhance patient safety and elevate inpatient diabetes care. The partnership positions Glytec as a preferred solution for Leapfrog member hospitals.

Strategic tierStrategicTypeGTM or Marketing Partner
Description

Glytec was awarded first Patient Safety Solutions Agreement with Premier in 2021, providing preferred pricing and access to Glytec's eGMS solutions for Premier member hospitals.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Monarch Medical Technologies makes EndoTool, the most direct competitor to Glucommander for hospital-based IV and SubQ insulin dosing. Glytec has published head-to-head clinical data showing 62% fewer severe hypoglycemia ADEs and 47% nursing time savings vs EndoTool, making this the closest comparable peer.

TypeDirect peer
Description

Voluntis (now part of Aptar Digital Health) developed Theraxium and other FDA-cleared insulin dose titration software, competing directly with Glucommander in the digital therapeutics and decision support category. Comparable in regulatory pathway (FDA SaMD) and target clinical use case.

TypeEmerging player
Description

DreaMed developed Advisor Pro and other AI-based insulin dosing decision support systems for diabetes management. After LifeScan acquisition, the company is positioned in both hospital and outpatient diabetes decision support, making it an adjacent competitor with similar clinical evidence-based positioning.

TypeBroad incumbent
Description

Epic is the largest US hospital EHR vendor and a current integration partner of Glytec. Epic includes built-in insulin dosing calculators and weight-based protocols that compete in the same clinical workflow as Glucommander, particularly for hospitals with less complex glycemic needs. Glytec publishes favorable outcomes comparisons vs Epic DIY approaches.

5Oracle Health (Cerner)
TypeBroad incumbent
Description

Oracle Health (formerly Cerner) is a major US hospital EHR vendor and Glytec integration partner. Like Epic, Oracle Health provides embedded clinical decision support that competes at the lower end of glycemic management complexity, though it remains a partner for hospital customers seeking best-of-breed dosing.

TypeBroad incumbent
Description

Medtronic operates a major diabetes business including insulin pumps and the MiniMed 780G automated insulin delivery system. While focused on outpatient/closed-loop delivery rather than hospital dosing, Medtronic is a relevant adjacent player in the broader diabetes management technology category and a potential strategic acquirer.

TypeBroad incumbent
Description

Dexcom is the dominant US continuous glucose monitoring (CGM) vendor, providing glucose data inputs to hospital glycemic management workflows. While not a dosing competitor, Dexcom's data feeds into Glytec's dosing recommendations and they could partner or compete for hospital diabetes technology budgets.

TypeEmerging player
Description

Roche is both a current technology partner (Roche-Glytec point-of-care integration) and a broader diabetes management player. The partnership validates interoperability but also positions Roche as a strategic peer that could choose to build or acquire competing dosing capabilities.

TypeEmerging player
Description

Stanson Health, a Premier company, provides clinical decision support solutions that include some glycemic management workflows. As a Premier-affiliated vendor, it competes for some of the same hospital CDS budget that Glytec targets through its Premier partnership.

TypeBroad incumbent
Description

Health Catalyst is a healthcare analytics and outcomes improvement platform serving US hospitals. Its population health and quality reporting capabilities overlap with Glytec's Performance Insights and Population Health pillars, making it a relevant adjacent competitor for analytics-driven glycemic management budget.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Glytec

Clinical Decision Support Softwareglytec.com

Glytec is a U.S.-based healthcare technology company that sells GlytecOne, an FDA-cleared, cloud-based glycemic management platform anchored by the Glucommander insulin dosing algorithm, to 400+ hospitals, health systems, and increasingly to health plans and value-based care organizations.

What Glytec does

Glytec is a Greenville/Atlanta-based healthcare technology company that develops and commercializes GlytecOne, a cloud-based, FDA-cleared platform for inpatient glycemic management. Its core engine, Glucommander, is a Class II Software as a Medical Device that has provided algorithm-based insulin dosing recommendations (IV and subcutaneous) since 2006 with zero recalls, and the platform extends into clinical workflow standardization, performance analytics, and population health intelligence across the care continuum. The company serves 400+ U.S. hospitals and health systems through a direct enterprise sales motion, with the 2026 CMS Hospital Harm eCQM mandate (NQF #3503e and #3533e) acting as a primary demand catalyst. Glytec is a wholly-owned subsidiary of Aseko, Inc., and sells primarily via annual subscription SaaS contracts whose pricing varies by hospital size and footprint, reporting customer outcomes of 6-8x ROI, up to 99.8% reduction in severe hypoglycemia events, and 50+ billion data points processed.

The company is led by President & CEO Patrick F. Cua (appointed 2024) and has raised a visible ~$78M across multiple venture and growth rounds, including a $36M growth investment in July 2025 led by Savitr Capital and Hayfin Capital Management. In March 2026 it announced relocation of global headquarters from Boston to Cobb County, Georgia, with 500 new jobs planned over several years. Strategic partners include Premier (Patient Safety Solutions Agreement), Leapfrog (Partner Advisory Committee), Roche (point-of-care device integration), University Hospitals, and Major Health Partners; the company also holds ISO 13485 and HITRUST CSF certifications and has secured 100+ patents and 100+ clinical publications.

Glytec firmographics

Firmographics
Name
Glytec
Legal name
Glytec, LLC
Website
https://glytec.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
Glytec is a U.S.-based healthcare technology company that sells GlytecOne, an FDA-cleared, cloud-based glycemic management platform anchored by the Glucommander insulin dosing algorithm, to 400+ hospitals, health systems, and increasingly to health plans and value-based care organizations.
Ownership category
akta.pro rank

Glytec industry classification

Industry
Product category
Clinical Decision Support Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Insulin management software
  • Glycemic management platform
  • FDA-cleared medical software
  • Clinical decision support
  • Diabetes therapy management

Where Glytec is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Glytec business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. SaaS Platform Subscription: Glytec operates as a SaaS healthcare technology company offering subscription-based access to its GlytecOne platform. The platform includes FDA-cleared Glucommander insulin dosing software and Command Center analytics. Revenue is generated through annual licensing agreements with hospitals and health systems, with pricing likely based on hospital size or patient volume.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise SaaS subscription for hospital glycemic management

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Glytec product offering

Product offering

Core offering

Glytec develops and sells the GlytecOne unified glycemic management SaaS platform for hospitals and health systems. Its core product is Glucommander, an FDA-cleared Class II Software as a Medical Device that provides algorithm-based IV and SubQ insulin dosing recommendations for hospitalized patients. The platform integrates bi-directionally with Epic, Oracle Health (Cerner), and Meditech EHRs and includes Command Center analytics, performance benchmarking, and CMS eCQM reporting.

Product overview

Glytec offers a unified platform architecture centered on GlytecOne, the first unified glycemic management platform that integrates four pillars: Care Enablement, Decision Support, Performance Insights, and Population Health. The platform's core product is Glucommander, an FDA-cleared Class II Software as a Medical Device providing algorithm-based IV (Glucommander IV) and subcutaneous (Glucommander SubQ) insulin dosing recommendations since 2006. Command Center serves as the clinical data visualization and analytics layer powering both Decision Support and Performance Insights, enabling current patient visibility, structured clinical review, and regulatory-ready eCQM reporting. The Population Health pillar extends enterprise glycemic intelligence to health system leaders and health plan partners. Glytec also offers the CMS Reporting CareKit as a preparation resource for the 2026 CMS mandate. Glytec serves 400+ hospitals and health systems with over 100 patents and 100+ clinical publications validating its outcomes.

Differentiator

Problem solved

Functional benefit

Brands

  • GlytecOne: The first unified glycemic management platform that integrates clinical decision support, workflow automation, performance analytics, and enterprise population health intelligence.
  • Glucommander
  • eGlycemic Management System (eGMS)
  • Command Center
  • Glucommander IV
  • Glucommander SubQ

Products and services

  • GlytecOne The first unified glycemic management platform that integrates clinical decision support, workflow automation, performance analytics, and enterprise population health intelligence. Built on four pillars: Care Enablement, Decision Support, Performance Insights, and Population Health. Connects care team members and hospital leaders with the data and tools to deliver safer, more consistent glucose management across the entire health system.
  • Glucommander FDA-cleared Class II Software as a Medical Device (SaMD) providing algorithm-based insulin dosing recommendations for hospitalized patients ages 2 and older. Available in two configurations: Glucommander IV for intravenous insulin dosing in acute and critical care settings, and Glucommander SubQ for subcutaneous basal-bolus insulin dosing in non-ICU and transitional care. Clinicians review and confirm all recommendations before administration. Has zero FDA recall record since 2006.
  • Command Center Clinical data visualization and analytics platform that provides healthcare professionals and administrators with organized displays of current and historical glycemic management information to support quality improvement, care coordination, and clinical review activities. Receives laboratory values, medication administration data, and clinical information from hospital EHR systems and presents this through dashboards, reports, and trend visualizations. Powers the Decision Support and Performance Insights pillars of GlytecOne.
  • Glytec CMS Reporting CareKit A comprehensive resource bundle designed to help hospitals prepare for the 2026 CMS Mandate requiring reporting of severe hypoglycemia (NQF #3503e) and severe hyperglycemia (NQF #3533e) as hospital harm eCQMs. Includes a CMS ruling summary, expert implementation timeline, and a CMS compliance checklist.
  • eGlycemic Management System (eGMS) Modularized solution for glycemic management across the care continuum, including Glucommander. Supports both IV and SubQ insulin dosing guidance. Superseded by GlytecOne in 2024 as the unified platform architecture.

Quantifiable outcome

  • Up to 99.8% reduction in severe hypoglycemia events
  • +9 more outcomes

Companies that use Glytec

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles2 records

Glytec technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature7 records

Glytec partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and strategic.

  • Advocate HealthcoreStrategic or Co-development PartnerGlytec and Advocate Health Beverly Knight Olson Children's Hospital won the top innovation award at the Society of Critical Care Medicine's Innovation Incubator for clinical evidence supporting software-guided insulin dosing in pediatric diabetic ketoacidosis patients. The study covered 1,372 children treated with Glucommander showing zero mortality. Glytec plans to continue collaboration through additional pediatric research and publications.
  • University HospitalscoreStrategic or Co-development PartnerGlytec and University Hospitals forged strategic partnership in 2024 to drive continued improvement in patient care and diabetes management. The partnership focuses on clinical collaboration and evidence development for glycemic management.
  • Major Health Partners (MHP)coreStrategic or Co-development PartnerGlytec and Major Health Partners forged strategic partnership in 2024 to drive continued improvement in patient care and diabetes management through Glytec's eGMS technology.
  • RochestrategicTechnology or IntegrationGlytec and Roche struck collaboration in 2022 on insulin management diagnostics on handheld point-of-care devices. The partnership enhances interoperability between Roche's diagnostic devices and Glytec's insulin management software.
  • CPS Solutions, LLCstrategicImplementation/ SI/ Consulting PartnerGlytec and CPS Solutions, LLC integrated in 2022 to provide evidence-based glycemic management. CPS is a leading provider of enterprise pharmacy solutions to hospitals and health systems.
  • Leapfrog GroupstrategicGTM or Marketing PartnerGlytec joined Leapfrog's Partner Advisory Committee in 2024 to enhance patient safety and elevate inpatient diabetes care. The partnership positions Glytec as a preferred solution for Leapfrog member hospitals.
  • PremierstrategicGTM or Marketing PartnerGlytec was awarded first Patient Safety Solutions Agreement with Premier in 2021, providing preferred pricing and access to Glytec's eGMS solutions for Premier member hospitals.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Glytec competitors and assessment

Company assessment

Direct peers

  • Monarch Medical Technologies (EndoTool): Monarch Medical Technologies makes EndoTool, the most direct competitor to Glucommander for hospital-based IV and SubQ insulin dosing. Glytec has published head-to-head clinical data showing 62% fewer severe hypoglycemia ADEs and 47% nursing time savings vs EndoTool, making this the closest comparable peer.
  • Voluntis (Aptar Digital Health): Voluntis (now part of Aptar Digital Health) developed Theraxium and other FDA-cleared insulin dose titration software, competing directly with Glucommander in the digital therapeutics and decision support category. Comparable in regulatory pathway (FDA SaMD) and target clinical use case.

Emerging players

  • DreaMed Diabetes (now part of LifeScan): DreaMed developed Advisor Pro and other AI-based insulin dosing decision support systems for diabetes management. After LifeScan acquisition, the company is positioned in both hospital and outpatient diabetes decision support, making it an adjacent competitor with similar clinical evidence-based positioning.
  • Roche Diabetes Care: Roche is both a current technology partner (Roche-Glytec point-of-care integration) and a broader diabetes management player. The partnership validates interoperability but also positions Roche as a strategic peer that could choose to build or acquire competing dosing capabilities.
  • Stanson Health (Premier): Stanson Health, a Premier company, provides clinical decision support solutions that include some glycemic management workflows. As a Premier-affiliated vendor, it competes for some of the same hospital CDS budget that Glytec targets through its Premier partnership.

Broad incumbents

  • Epic Systems: Epic is the largest US hospital EHR vendor and a current integration partner of Glytec. Epic includes built-in insulin dosing calculators and weight-based protocols that compete in the same clinical workflow as Glucommander, particularly for hospitals with less complex glycemic needs. Glytec publishes favorable outcomes comparisons vs Epic DIY approaches.
  • Oracle Health (Cerner): Oracle Health (formerly Cerner) is a major US hospital EHR vendor and Glytec integration partner. Like Epic, Oracle Health provides embedded clinical decision support that competes at the lower end of glycemic management complexity, though it remains a partner for hospital customers seeking best-of-breed dosing.
  • Medtronic (Diabetes Operating Unit): Medtronic operates a major diabetes business including insulin pumps and the MiniMed 780G automated insulin delivery system. While focused on outpatient/closed-loop delivery rather than hospital dosing, Medtronic is a relevant adjacent player in the broader diabetes management technology category and a potential strategic acquirer.
  • Dexcom: Dexcom is the dominant US continuous glucose monitoring (CGM) vendor, providing glucose data inputs to hospital glycemic management workflows. While not a dosing competitor, Dexcom's data feeds into Glytec's dosing recommendations and they could partner or compete for hospital diabetes technology budgets.
  • Health Catalyst: Health Catalyst is a healthcare analytics and outcomes improvement platform serving US hospitals. Its population health and quality reporting capabilities overlap with Glytec's Performance Insights and Population Health pillars, making it a relevant adjacent competitor for analytics-driven glycemic management budget.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Glytec social profiles

Digital presence

Glytec compliance and trust

Trust signal

Compliance3 records

Glytec financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Glytec leadership team

Management profile

Number of profiles

Profiles20 records

Glytec funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Glytec M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glytec

What does Glytec do?

Glytec develops and sells the GlytecOne unified glycemic management SaaS platform for hospitals and health systems. Its core product is Glucommander, an FDA-cleared Class II Software as a Medical Device that provides algorithm-based IV and SubQ insulin dosing recommendations for hospitalized patients. The platform integrates bi-directionally with Epic, Oracle Health (Cerner), and Meditech EHRs and includes Command Center analytics, performance benchmarking, and CMS eCQM reporting.

Is Glytec a public or private company?

Glytec is a private company. It is classified as venture growth investor backed and is currently operating.

When was Glytec founded?

Glytec was founded in 2006. It employs 51 to 100 people.

Where is Glytec based?

Glytec is headquartered in Atlanta, United States, in the North America region.

How does Glytec make money?

One revenue line is on record: saaS Platform Subscription.

Who are Glytec's main competitors?

Direct peers on record are Monarch Medical Technologies (EndoTool) and Voluntis (Aptar Digital Health). Emerging players are DreaMed Diabetes (now part of LifeScan), Roche Diabetes Care and Stanson Health (Premier). Broad incumbents are Epic Systems, Oracle Health (Cerner), Medtronic (Diabetes Operating Unit), Dexcom and Health Catalyst.

Does Glytec have an API?

No public API is recorded for Glytec.

What industry is Glytec in?

Glytec's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 54151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlytec Recognized Among TIME's World's Top HealthTech CompaniesGlytec was named to TIME's World's Top HealthTech Companies for 2026. The company's GlytecOne portfolio includes Glucommander, an FDA-cleared insulin dosing system, and addresses five high-acuity conditions. CEO Patrick Cua said the recognition reflects trust and aims to help clinicians deliver better care.Medical Device NetworkFDA grants breakthrough designation to Glytec’s Glucommander PediatricsThe FDA granted breakthrough device designation to Glytec's Glucommander Pediatrics, an insulin dosing algorithm for hospitalised newborns and infants under two. The prescription-only product is separate from Glytec's existing Glucommander technology and targets conditions like diabetic ketoacidosis and hyperglycaemia of prematurity. Glytec expects similar technology to become available for patients under two.Mpo-magGlytec Wins FDA Breakthrough Nod for Infant Insulin Dosing TechGlytec received FDA breakthrough status for Glucommander Pediatrics, a computerized insulin dosing algorithm for hospitalized neonates and infants. The software will be a separate prescription-only product for continuous IV insulin in life-threatening conditions. It aims to extend benefits from adult intensive care to infants under two.YahooFDA grants breakthrough designation to Glytec’s Glucommander PediatricsThe FDA granted breakthrough device designation to Glytec's Glucommander Pediatrics algorithm for hospitalised newborns and infants under two requiring continuous intravenous insulin infusion. The algorithm targets conditions like diabetic ketoacidosis and hyperglycaemia of prematurity, extending Glytec's technology into neonatal and paediatric intensive care units.YahooFDA grants breakthrough designation to Glytec’s Glucommander PediatricsThe FDA granted breakthrough device designation to Glytec's Glucommander Pediatrics, an insulin dosing algorithm for hospitalised newborns and infants under two. The algorithm targets critically ill patients with conditions like diabetic ketoacidosis, and Glytec expects similar technology to become available for this age group.PR NewswireGlytec Receives FDA Breakthrough Device Designation for Glucommander Pediatrics, an Insulin Management Technology for Hospitalized Newborns and InfantsGlytec received FDA Breakthrough Device Designation for Glucommander Pediatrics, an insulin dosing algorithm for hospitalized newborns and infants under two years. The designation covers a population without FDA-cleared dosing software, and the product will be prescription-only for continuous IV insulin infusion.FITSNewsLawsuit Accuses Prisma of Reverse Engineering a $60 Million Medical PlatformGlytec LLC, a Georgia-based healthcare technology company, filed a federal lawsuit in South Carolina accusing Prisma Health, the state's largest hospital system, of illegally reverse engineering its proprietary FDA-cleared insulin-management software Glucommander after deciding not to pay approximately $1 million in annual licensing fees. Glytec claims it spent nearly two decades and more than $60 million developing the software, and is seeking damages estimated to exceed $10 million along with permanent injunctive relief. A federal judge issued a preliminary injunction restricting Prisma from marketing or disseminating the allegedly infringing software while the case proceeds, though the court allowed continued internal use for patient care.PR NewswireGlytec and Advocate Health Win Top Innovation Award for Pediatric Insulin SafetyGlytec and Advocate Health Beverly Knight Olson Children's Hospital won the top innovation award at the Society of Critical Care Medicine's Innovation Incubator for clinical evidence supporting software-guided insulin dosing in pediatric diabetic ketoacidosis patients. The study covered 1,372 children treated with Glytec's Glucommander system, showing zero mortality and very low rates of dangerously low blood sugar. Glytec plans to continue its collaboration with Advocate Health through additional pediatric research and publications to expand evidence across pediatric care settings.Medical Device and Diagnostic industryGlytec Moves HQ to Atlanta, Adds 500 JobsGlytec, a healthcare technology company and creator of the GlytecOne insulin management platform, has announced plans to relocate its headquarters to the Atlanta, Georgia area. Through this move, Glytec will bring 500 new jobs to Cobb County, marking a significant expansion for the company which currently serves over 400 hospitals and health systems nationwide with its insulin dosing software. The relocation underscores Georgia's growing reputation as a hub for health tech and life sciences innovation, competing with traditional medtech centers like Boston, North Carolina, and Minneapolis.Business Facilities MagazineHealth Tech Company To Relocate HQ To Metro Atlanta, Add 500 JobsGlytec, a healthcare information technology company, announced it will relocate its global headquarters to Cobb County, Georgia, creating 500 new jobs over the next several years. The company, founded by a Georgia endocrinologist, specializes in software managing insulin levels for diabetic patients in hospitals. The relocation underscores metro Atlanta's growing appeal as a corporate headquarters destination, following Yamaha Motor Co.'s announcement earlier this month that it will move its U.S. headquarters from California to Kennesaw, Georgia.